Opthea's Role in Advancing Ophthalmology
Opthea Limited (NASDAQ: OPT), a clinical-stage biopharmaceutical company, is committed to developing innovative therapies aimed at treating prevalent and progressive retinal diseases, particularly focusing on conditions such as wet age-related macular degeneration (wet AMD). The company has exciting news as it prepares to engage with investors during the UBS Virtual Ophthalmology Day.
Event Details
On October 2, leaders from Opthea will be actively participating in a fireside chat followed by one-on-one investor meetings. This event represents a significant opportunity for Opthea to showcase its advancing research and developments in eye care.
Insight into Opthea's Innovations
At the forefront of Opthea's innovative efforts is their leading drug candidate, sozinibercept. This innovative therapy is currently undergoing evaluation in two pivotal Phase 3 clinical trials named COAST and ShORe. These studies aim to demonstrate its effectiveness in combination with standard anti-VEGF-A therapies, potentially enhancing vision outcomes for patients.
Focus on Retinal Diseases
Retinal diseases, such as wet AMD and diabetic macular edema (DME), critically impact patient vision and quality of life. Opthea is on a mission to fill the gaps in treatment options available for these conditions, addressing pressing unmet needs in ocular health.
Meet the Leaders
Frederic Guerard, PharmD and CEO of Opthea, will be leading the discussions during the UBS event, sharing insights about the company's journey and pipeline. His expertise and leadership position Opthea as an influencer in the field of ophthalmology.
Accessing the Webcast
For those interested in attending the discussion virtually, a webcast will be available. Participants can also find further information in the Investor Relations section of Opthea's website, giving a comprehensive view of their ongoing projects and aspirations.
About Opthea Limited
Opthea has carved a niche in the field of biopharmaceuticals by focusing on developing novel therapies that specifically target retinal diseases. Their commitment to research is indicative of their vision to improve patient care and treatment outcomes.
Commitment to Stakeholders
Continued communication with stakeholders remains a priority for Opthea. They encourage inquiries from investors and media alike to ensure transparency and collaboration within the healthcare community.
Frequently Asked Questions
What is Opthea's focus in biopharmaceuticals?
Opthea is dedicated to developing innovative therapies for retinal diseases, particularly wet AMD and diabetic macular edema.
When is the UBS Virtual Ophthalmology Day?
The event is scheduled for October 2, 2024, during which Opthea will participate in a fireside chat.
Who is the key presenter from Opthea?
Frederic Guerard, PharmD and CEO of Opthea will be leading the discussions at the event.
How can I access the webcast of the event?
The webcast will be available online, and details can be found on Opthea's Investor Relations page.
What is sozinibercept?
Sozinibercept is Opthea's lead product candidate currently being tested in pivotal clinical trials aimed at enhancing treatment efficacy for retinal diseases.
